Channel BannerChannel Banner
ucqItNWgHv4ucqItNWgHv4

Viswa Colluru, Enveda | theCUBE + NYSE Wired: NYSE Rx

16,398
Socialcounts.OrgEnter Fullscreen (f)
132
likes
0
comments
daily view 0
monthly view 0

Share

Live Analytics

Comments 0

Viswa Colluru, Enveda | theCUBE + NYSE Wired: NYSE Rx Analytics Table

Income Estimates for Viswa Colluru, Enveda | theCUBE + NYSE Wired: NYSE Rx

Based on this YouTube video's total view count of 16.3K views and industry-standard rates, the estimated total earning is $11 - $33 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

About Viswa Colluru, Enveda | theCUBE + NYSE Wired: NYSE Rx

Explore Viswa Colluru, Enveda | theCUBE + NYSE Wired: NYSE Rx with 16,398 views, 132 likes, and 0 comments. Experience the impact of this video content that has captured audience attention.

In this interview from theCUBE + NYSE Wired: NYSE Rx, Viswa Colluru, founder of Enveda Biosciences, joins theCUBE + NYSE Wired's Gemma Allen to discuss how AI is turning nature's four-billion-year chemical library into a new engine for drug discovery. Colluru traces Enveda's origins to a chemistry-first bet that evolution has already optimized molecules like metformin and aspirin, and explains how mass spectrometry data turned out to be perfectly suited for large language models to decode. He details the company's track record: 17 molecules discovered, 6 advanced through IND-enabling studies, 3 now in clinical trials, with an 89% success rate roughly 7 to 8 times the industry average. The conversation explores the economics of building a biotech company around AI, including Enveda's recently closed $311 million Series E and its decision to run clinical trials in-house rather than through a contract research organization. Colluru shares the personal story behind his mission — losing his mother to chronic myeloid leukemia before treatments caught up — and how that urgency shapes Enveda's push to compress drug discovery from 4 years and $10 million to about a year and $1 million. He also touches on how GLP-1 drugs are set to outpace generative AI revenue this year, a sign that biotech's economic upside extends well beyond software. From vertically integrated discovery to self-run clinical operations, Colluru lays out a roadmap for how AI-native biotechs can get real medicines to patients faster. Find more SiliconANGLE news and analysis https://siliconangle.com/ Follow theCUBE's wall-to-wall event coverage https://siliconangle.com/events/ Learn about the latest theCUBE events https://www.thecube.net/ 00:00 - AI-Driven Discovery: Bridging Natural Medicines and Modern Innovation 03:27 - Revolutionizing Progress: AI and Mass Spectrometry at Enveda 06:33 - Revolutionizing Medicine: AI in Drug Discovery and Clinical Trials 09:49 - Overcoming Obstacles in Drug Development: Innovative Approaches 14:35 - Driving Forces: Innovation and Vision in Biotech 16:46 - Envisioning Tomorrow: Reflections and Pathways #theCUBE #NYSERx #theCUBEresearch #NYSEWired #EnvedaBiosciences #AI #DrugDiscovery

About YouTube Real-Time View Count

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.

Embed Widget

Parameters:

  • fullscreen=true - Fullscreen counter
  • graph=true - Live graph chart
  • counter=0/1/2 - Select counter (0=likes, 1=views, 2=comments)
URL

Click to copy the embed URL to your clipboard